
## BOOST Education and Office Hours: COVID and Vaccination Status Update

Jeremy Bischoff, LHNA, BS
State Quality Manager-Kentucky, CMS
Vaccination Lead






## **About Alliant Health Solutions**



## **Current State: COVID-19**

The blue bars show daily cases. The red line is the 7-day moving average of cases. The orange line shows the percent of NAAT tests reported in the last 7 days that were positive for COVID-19.








## **Current State: COVID-19**


The blue bars show daily cases. The red line is the 7-day moving average of cases. The orange line represents the 7-day average of the number of prevalent patients hospitalized with confirmed COVID-19.








### **Resident Cases of COVID-19**






## **Staff Cases of COVID-19**





## **Wastewater Surveillance**




Current SARS-CoV-2 virus levels by site, United States

Curr	ent
------	-----

Current			
virus levels category	Num. sites		Category change in last 7 days
New Site	193	20	1%
0% to 19%	7	1	- 13%
20% to 39%	54	6	- 22%
40% to 59%	229	24	- 2%
60% to 79%	330	35	- 3%
80% to 100%	139	15	6%



### **Current COVID-19 Variant**





## **The Three Pillars**

Up to Date Vaccinate (booster for all eligible)

**PPE and Infection Control** 

**Testing** 




## **Vaccine Effectiveness**

SARS-CoV-2 infection	3 doses mRNA	69%
Hospitalizations	3 doses mRNA	90%> 84% for Omicron
ED visit	3 doses mRNA	83%
Mechanical ventilation or death	3 doses mRNA	94%

https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness




## **Vaccine Effectiveness in LTC**



Crude weekly rates of reported confirmed SARS-CoV-2 infection among skilled nursing facility residents, by vaccination status and resident-week — National Healthcare Safety Network, United States, February 14–March 27, 2022 (Prasad N, Derado G, Nanduri SA, et al. MMWR 2022;71:633–637).



## Effect of 3<sup>rd</sup> vs 4<sup>th</sup> Dose Against Omicron



https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2793699



## **Checklist**

- ☐ Up-to-date vaccine
  - Residents
  - STAFF
- ☐ PPE and infection control
  - Staff
  - Residents
  - Visitors
- ☐ Test early
  - Cohort




## **Preventing Spread**







- Risk of giving to resident





- Risk of giving to resident





- Healthier staff
- Risk of giving to resident

Resident



- Risk of giving to resident



Risk of giving to resident





## **Therapeutic Considerations**

#### PATIENT DISPOSITION

Does Not Require
Hospitalization or
Supplemental Oxygen

#### PANEL'S RECOMMENDATIONS

All patients should be offered symptomatic management (AIII).

For patients who are at high risk of progressing to severe COVID-19, a use 1 of the following treatment options:

#### **Preferred Therapies**

Listed in order of preference:

- Ritonavir-boosted nirmatrelvir (Paxlovid)<sup>b,c</sup> (Alla)
- Remdesivir<sup>c,d</sup> (Blla)


#### **Alternative Therapies**

For use <u>ONLY</u> when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:

- Bebtelovimab<sup>e</sup> (CIII)
- Molnupiravir<sup>c,f</sup> (Clla)

The Panel recommends against the use of dexamethasone<sup>g</sup> or other systemic corticosteroids in the absence of another indication (AIII).







## What's New in COVID-19 Vaccination News?


## Novavax: EUA July 13, 2022

**Number of Shots:** Two doses in the primary series, given three-eight weeks apart. People who are moderately or severely immunocompromised should also receive two doses, given three weeks apart (a third primary dose is not currently authorized).

Booster Shot: Novavax COVID-19 vaccine is not authorized for use as a booster dose.



## **Novavax: Efficacy**



https://www.nejm.org/doi/full/10.1056/NEJMoa2107659



## **Novavax: Contraindications**

Do not administer the Novavax COVID-19 vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 vaccine, Adjuvanted (see full EUA prescribing information).

https://www.fda.gov/media/159897/download



### **Novavax: Side Effects**

- Site pain/tenderness (82.2%),
- Fatigue/malaise (62.0%),
- Muscle pain (54.1%),
- Headache (52.9%),
- Joint pain (25.4%),
- Nausea/vomiting (15.6%),
- Injection site redness (7.0%),
- Injection site swelling (6.3%),
- Fever (6.0%).
- Myocarditis, pericarditis, chills, injection site pruritus, hypersensitivity reactions, and lymphadenopathy-related reactions have been reported (RARE) following administration of the Novavax COVID-19 Vaccine, Adjuvanted.

https://www.fda.gov/media/159897/download



## **Questions?**





# **Nursing Home and Partnership for Community Health:**

CMS 12th SOW GOALS



#### OPIOID UTILIZATION AND MISUSE

Promote opioid best practices

Reduce opioid adverse drug events in all settings



## PATIENT SAFETY

Reduce hospitalizations due to c. diff

Reduce adverse drug events

Reduce facility acquired infections



#### CHRONIC DISEASE SELF-MANAGEMENT

Increase instances of adequately diagnosed and controlled hypertension

Increase use of cardiac rehabilitation programs

Reduce instances of uncontrolled diabetes

Identify patients at highrisk for kidney disease and improve outcomes



## CARE COORDINATION

Convene community coalitions

Reduce avoidable readmissions, admissions to hospitals and preventable emergency department visits

Identify and promote optimal care for super utilizers



#### COVID-19

Support nursing homes by establishing a safe visitor policy and cohort plan

Provide virtual events to support infection control and prevention

Support nursing homes and community coalitions with emergency preparedness plans



#### **IMMUNIZATION**

Increase influenza, pneumococcal, and COVID-19 vaccination rates



#### **TRAINING**

Encourage completion of infection control and prevention trainings by front line clinical and management staff







Julie Kueker

<u>Julie.Kueker@AlliantHealth.org</u>

Alabama, Florida and Louisiana




Leighann Sauls

<u>Leighann.Sauls@AlliantHealth.org</u>

Georgia, Kentucky, North Carolina and Tennessee

















This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) and Hospital Quality Improvement Contractor (HQIC) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHSQIN-QIO TO1-CH TO1-NH--2364-07/27/22